Program
AR882
A development code. Also written as “AR882 75 mg”, “AR882 50 mg” and “AR882 Dose 1”.
Its studies are mostly in Arthritis, Gouty · Hyperuricemia · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Swedish Orphan Biovitrum | 91 open or running | phase 3since May 28, 2024 | Oct 25, 2019 | Nov 2026phase 2 · NCT07116746 |
| Guangzhou Ruianbo Pharmaceutical Technology | 11 open or running | phase 3since Sep 17, 2024 | Sep 17, 2024 | none ahead |
Also a collaborator on its studies: iqvia-pty-ltd and celerion.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 25, 2019First study: phase 2 study in HyperuricemiaNew to Swedish Orphan BiovitrumSwedish Orphan Biovitrum · NCT04155918 · 30 enrolled · New Zealand
- Mar 10, 2020Phase 1 study in Healthy VolunteersSwedish Orphan Biovitrum · NCT04347005 · 64 enrolled · Australia
- Aug 6, 2020Phase 1 study in Healthy VolunteersSwedish Orphan Biovitrum · NCT04508426 · 6 enrolled · United States
- Nov 18, 2020Phase 1 study in Renal InsufficiencySwedish Orphan Biovitrum · NCT04646889 · 46 enrolled · United States, New Zealand
- Oct 20, 2021Phase 2 study in GoutSwedish Orphan Biovitrum · NCT05119686 · 140 enrolled · United States, Australia, Taiwan
- Feb 15, 2022Phase 2 study in GoutSwedish Orphan Biovitrum · NCT05253833 · 42 enrolled · United States, New Zealand, Taiwan
- May 28, 2024Phase 3 study in GoutSwedish Orphan Biovitrum · NCT06439602 · 818 enrolled · United States, Australia, Hong Kong and more
- Sep 17, 2024Guangzhou Ruianbo Pharmaceutical Technology's first study: phase 3 study in HyperuricemiaNew to Guangzhou Ruianbo Pharmaceutical TechnologyGuangzhou Ruianbo Pharmaceutical Technology · NCT06603142 · 636 enrolled · China
- Feb 21, 2025Phase 3 study in GoutSwedish Orphan Biovitrum · NCT06846515 · 866 enrolled · United States
- Aug 7, 2025Phase 2 study in GoutSwedish Orphan Biovitrum · NCT07116746 · 15 enrolled · United States
Ahead
- Nov 2026Primary completion: phase 2 study in GoutSwedish Orphan Biovitrum · NCT07116746
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07116746Gout · United States | 2 | Active, not recruiting | Swedish Orphan Biovitrum | Nov 2026 | 15 |
| NCT06846515Gout · United States | 3 | Completed | Swedish Orphan Biovitrum | Aug 31, 2026 | 866 |
| NCT06603142Hyperuricemia · China | 3 | Active, not recruiting | Guangzhou Ruianbo Pharmaceutical Technology | Apr 2026 | 636 |
| NCT06439602Gout · United States, Australia, Hong Kong and more | 3 | Completed | Swedish Orphan Biovitrum | Mar 20, 2026 | 818 |
| NCT05253833Gout · United States, New Zealand, Taiwan | 2 | Completed | Swedish Orphan Biovitrum | Aug 13, 2024 | 42 |
| NCT05119686Gout · United States, Australia, Taiwan | 2 | Completed | Swedish Orphan Biovitrum | Nov 17, 2022 | 140 |
| NCT04646889Renal Insufficiency · United States, New Zealand | 1 | Completed | Swedish Orphan Biovitrum | Jun 27, 2022 | 46 |
| NCT04508426Healthy Volunteers · United States | 1 | Completed | Swedish Orphan Biovitrum | Aug 12, 2020 | 6 |
| NCT04347005Healthy Volunteers · Australia | 1 | Completed | Swedish Orphan Biovitrum | Jul 31, 2019 | 64 |
| NCT04155918Hyperuricemia · New Zealand | 2 | Completed | Swedish Orphan Biovitrum | Sep 3, 2020 | 30 |
How it is read
Names in the registry
- “AR882 75 mg”, 3 entries
- “AR882 50 mg”, 2 entries
- “AR882 Dose 1”, 2 entries
- “AR882 Dose 2”, 2 entries
- “AR882 25MG”, 1 entry
Codes read as this program: AR882.
Conditions, from the studies’ own filings
- Arthritis, Gouty, 5 studies
- Hyperuricemia, 2 studies
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.